353 related articles for article (PubMed ID: 20072152)
1. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Kim K; Kim SJ; Voelter V; Suh C; Yoon SS; Lee JJ; Kwak JY; Ryoo HM; Kim YS; Moon JH; Park SK; Kim SH; Mun YC; Kim JS; Eom HS; Jo DY; Jun HJ; Kim KH; Lee JO; Lee JH; Min CK;
Ann Hematol; 2014 Jan; 93(1):113-21. PubMed ID: 24026427
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
6. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
8. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
9. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Dimopoulos MA; Chen C; Spencer A; Niesvizky R; Attal M; Stadtmauer EA; Petrucci MT; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Leukemia; 2009 Nov; 23(11):2147-52. PubMed ID: 19626046
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
15. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Zago M; Oehrlein K; Rendl C; Hahn-Ast C; Kanz L; Weisel K
Ann Hematol; 2014 Dec; 93(12):1993-9. PubMed ID: 24974802
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
